Malaria causes high levels of morbidity and mortality in human beings worldwide. According to the World Health Organization (WHO), about half a million people die of this disease each …
Background The efficacy and safety of the RTS, S/AS01 candidate malaria vaccine during 18 months of follow-up have been published previously. Herein, we report the final results …
T Lagousi, P Basdeki, J Routsias, V Spoulou - Vaccines, 2019 - mdpi.com
Non-serotype-specific protein-based pneumococcal vaccines have received extensive research focus due to the limitations of polysaccharide-based vaccines. Pneumococcal …
Identification of potential drug targets as well as development of novel antimalarial chemotherapies with unique mode of actions due to drug resistance by Plasmodium …
MJ Levin - Current opinion in immunology, 2012 - Elsevier
Varicella-zoster virus (VZV) T-cell-mediated immunity (VZV-CMI) in older persons prevents latent VZV in sensory neurons from reactivating to cause herpes zoster. VZV-CMI declines …
Background Dengue is one of the fastest spreading vector-borne diseases, caused by four antigenically distinct dengue viruses (DENVs). Antibodies against DENVs are responsible …
S Menzel, T Holland, A Boes, H Spiegel… - Frontiers in plant …, 2016 - frontiersin.org
Plants provide an advantageous expression platform for biopharmaceutical proteins because of their low pathogen burden and potential for inexpensive, large-scale production …
JJ Moehrle - Tropical Medicine and Infectious Disease, 2022 - mdpi.com
Drug discovery for malaria has traditionally focused on orally available drugs that kill the abundant, parasitic blood stage. Recently, there has also been an interest in injectable …
S Menzel, T Holland, A Boes, H Spiegel… - Protein Expression and …, 2018 - Elsevier
Plants as a platform for recombinant protein expression are now economically comparable to well-established systems, such as microbes and mammalian cells, thanks to advantages …